Indaptus Therapeutics Files 8-K on Agreements
Ticker: INDP · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1857044
| Field | Detail |
|---|---|
| Company | Indaptus Therapeutics, INC. (INDP) |
| Form Type | 8-K |
| Filed Date | Feb 12, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01, $20.0 million, $25,000, $0.81722 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
TL;DR
Indaptus Therapeutics filed an 8-K on Feb 12, 2025, covering new deals and stock sales.
AI Summary
On February 12, 2025, Indaptus Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The company, formerly known as Intec Parent Inc., is incorporated in Delaware and headquartered in New York.
Why It Matters
This filing indicates significant corporate actions, including new agreements and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes indicate dilution or less transparent capital raising activities.
Key Numbers
- 001-40652 — SEC File Number (Identifies the company's filing with the SEC.)
- 86-3158720 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Indaptus Therapeutics, Inc. (company) — Registrant
- February 12, 2025 (date) — Filing date
- Intec Parent Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- New York (location) — Principal executive offices city
- 3 Columbus Circle (address) — Principal executive offices street
FAQ
What type of material definitive agreement was entered into by Indaptus Therapeutics?
The filing does not specify the nature of the material definitive agreement, only that one was entered into.
What was the former name of Indaptus Therapeutics?
The former name of Indaptus Therapeutics was Intec Parent Inc.
On what date was this 8-K report filed?
This 8-K report was filed on February 12, 2025.
Where are Indaptus Therapeutics' principal executive offices located?
Indaptus Therapeutics' principal executive offices are located at 3 Columbus Circle, 15th Floor, New York, NY 10019.
What are the key items reported in this 8-K filing?
The key items reported are Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, and Financial Statements and Exhibits.
Filing Stats: 1,329 words · 5 min read · ~4 pages · Grade level 13.2 · Accepted 2025-02-12 09:22:00
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value INDP Nasdaq Capital Mark
- $20.0 million — ch such occurrence, an "Advance") up to $20.0 million (the "Commitment Amount") o f the Compa
- $25,000 — t Shares") to Yorkville and also paid a $25,000 structuring fee to Yorkville. Under t
- $0.81722 — Stock under the SEPA equals or exceeds $0.81722 per share (which represents the lower o
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex10-1.htm (EX-10.1) — 317KB
- 0001493152-25-006052.txt ( ) — 592KB
- indp-20250212.xsd (EX-101.SCH) — 3KB
- indp-20250212_lab.xml (EX-101.LAB) — 33KB
- indp-20250212_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 12, 2025 INDAPTUS THERAPEUTICS, INC. By: /s/ Nir Sassi Name: Nir Sassi Title: Chief Financial Officer